Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Abvc Biopharma (ABVC) Net Income towards Common Stockholders (2016 - 2025)

Abvc Biopharma (ABVC) has disclosed Net Income towards Common Stockholders for 13 consecutive years, with -$3.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Income towards Common Stockholders fell 129.03% year-over-year to -$3.0 million, compared with a TTM value of -$5.7 million through Dec 2025, down 207.8%, and an annual FY2025 reading of -$8.4 million, down 259.29% over the prior year.
  • Net Income towards Common Stockholders was -$3.0 million for Q4 2025 at Abvc Biopharma, down from -$1.3 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $10.4 million in Q4 2024 and bottomed at -$7.9 million in Q4 2021.
  • Average Net Income towards Common Stockholders over 5 years is -$793316.1, with a median of -$1.9 million recorded in 2022.
  • The sharpest move saw Net Income towards Common Stockholders surged 229.66% in 2022, then crashed 620.69% in 2024.
  • Year by year, Net Income towards Common Stockholders stood at -$7.9 million in 2021, then soared by 229.66% to $10.3 million in 2022, then crashed by 39.62% to $6.2 million in 2023, then surged by 67.33% to $10.4 million in 2024, then tumbled by 129.03% to -$3.0 million in 2025.
  • Business Quant data shows Net Income towards Common Stockholders for ABVC at -$3.0 million in Q4 2025, -$1.3 million in Q3 2025, and -$2.3 million in Q2 2025.